Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

New

Galactose-Deficient IgA1 (Human) ELISA Kit

An Indirect ELISA kit for quantitative measurement of Galactose-Deficient IgA1 in human serum, plasma, tissue lysates, and other biological fluids
Catalog #: E5019
$750.00

Product Details

Cat # +Size E5019-100
Size 96 assays
Detection Method Absorbance (450 nm)
Species Reactivity Human
Applications Indirect ELISA kit for quantitative measurement of Galactose-Deficient IgA1 in serum, plasma, cell and tissue lysates, and other biological fluids
Features & Benefits ● Detection range: 14.06 – 900 ng/ml
● Recovery range: 85 - 105% for normal human serum and plasma samples
● This Indirect ELISA is highly sensitive and highly specific for the detection of Galactose-Deficient IgA1 in human samples. There is no significant cross-reactivity or interference between Galactose-Deficient IgA1 and analogues
● Sensitivity: 8 ng/ml
● Assay Precision: Intra-Assay CV and Inter-Assay CV < 10%
Kit Components ● Micro ELISA plate
● Wash Buffer (25X)
● Plate sealers
● Standard (Lyophilized) (900 ng)
● Sample/Standard Dilution Buffer
● Biotin-labeled Antibody
● Antibody Dilution Buffer
● HRP-Streptavidin Conjugate (SABC)
● SABC Dilution Buffer
● TMB Substrate Solution
● Stop Solution
Storage Conditions 4ºC
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.

Details

Galactose-deficient IgA1 (Gd-IgA1) is an immune complex that plays a critical role in IgA nephropathy. IgA nephropathy (IgAN) or Berger’s disease is the most common form of primary glomerulonephritis in Asian countries. The renal disorder occurs when IgA1 deposits in the glomeruli of the kidney. IgA1 deposition causes inflammation of the kidneys and hampers its ability to filter waste and extra fluid from the blood. In IgA nephropathy, the IgA1 is aberrantly glycosylated; it lacks a galactose residue at one or more O-glycan sites in the hinge region due to reduced activity or expression of β-1,3-galactosyltransferase (C1GALT1), an enzyme responsible for the addition of Galactose residue. In the absence of a galactose residue, IgA1 molecules are presented as autoantigens and are attacked by IgA1 glycan-specific autoantibodies. Patients suffering from IgA nephropathy have elevated levels of Gd-IgA1 in their serum. Gd-IgA1 is known to play a critical role in the progression and pathogenesis of IgA nephropathy; hence Gd-IgA1 may serve as a promising biomarker for IgA nephropathy. BioVision’s Galactose-deficient IgA1 (Human) ELISA kit quantitatively measures Galactose-deficient IgA1 in human serum, plasma, and other biological fluids. The kit is based on Indirect ELISA principle. Test samples, Standards, and Biotinylated Detection antibody are added to the wells pre-coated with the antigen and then washed with Wash Buffer. HRP-Streptavidin is added to the plate, and post-incubation any unattached conjugates are washed off by Wash Buffer. The HRP enzymatic reaction is detected using TMB-substrate. Finally, an acidic stop solution terminates the enzymatic reaction. The color developed is directly proportional to the amount of Galactose-deficient IgA1 in the sample.


Why buy BioVision Products?
Innovation
Affordability
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.